Welcome to our dedicated page for BOSTON SCIENTIFIC SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BOSTON SCIENTIFIC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BOSTON SCIENTIFIC's regulatory disclosures and financial reporting.
BOSTON SCIENTIFIC CORP executive Arthur C. Butcher reported routine equity compensation activity. On May 2, 2026, he exercised 2,102 Restricted Stock Units, receiving the same number of common shares. These RSUs each represent a commitment to issue one share of Boston Scientific common stock.
To cover tax obligations, 1,007 common shares were disposed of through a tax-withholding transaction at $56.50 per share, which is not an open-market sale. After these transactions, he holds 56,887 common shares directly and 20,228 shares indirectly through the company’s 401(k) Retirement Savings Plan.
Boston Scientific delivered strong first-quarter 2026 results, with net sales of $5.203 billion, up 11.6% from $4.663 billion, driven by double-digit growth in Cardiovascular and MedSurg businesses. Net income attributable to common stockholders rose to $1.341 billion from $674 million, or diluted EPS of $0.90 versus $0.45.
Adjusted diluted EPS was $0.80, up 6.0%. Organic and operational net sales growth were both 9.4%, reflecting innovation and commercial execution, particularly in Electrophysiology and Interventional Cardiology & Vascular Therapies. Cash from operations was $348 million, with higher acquisition spending and capex leading to lower cash balances.
The company continued its acquisition strategy, closing the Nalu Medical deal (total preliminary consideration $588 million), completing the prior Cortex acquisition, signing to buy Scivita Medical and agreeing to acquire Penumbra for about $14.5 billion. It added new revolving credit and term loan facilities to support funding and ended the quarter with total assets of $44.351 billion, senior notes of $10.935 billion and a leverage ratio of 1.87x versus a 4.25x covenant limit.
Boston Scientific Corp disclosure: Vanguard Capital Management reports beneficial ownership of 111,127,205 shares of Common Stock, representing 7.47% of the class. The filing shows sole dispositive power over 111,127,205 shares and sole voting power over 14,715,637 shares, signed 04/29/2026.
Boston Scientific reported strong first quarter 2026 results, with net sales of $5.203 billion, up 11.6% year over year on a reported basis and 9.4% on an operational and organic basis. GAAP net income attributable to common stockholders rose to $1.341 billion, or $0.90 per diluted share, compared to $0.45 a year earlier, while adjusted EPS increased to $0.80 from $0.75, slightly above guidance.
Growth was broad-based, led by Cardiovascular net sales up 13.5% reported and 11.2% operational and organic, and MedSurg up 7.8% reported. By region, net sales grew 10.9% in the U.S., 14.7% in Asia-Pacific and 19.0% in Latin America and Canada on a reported basis.
For full year 2026, the company now expects net sales growth of 7.0–8.5% reported and 6.5–8.0% organic, and adjusted EPS of $3.34–$3.41. Second quarter 2026 guidance calls for reported net sales growth of 5.5–7.5%, organic growth of 5.0–7.0%, and adjusted EPS of $0.82–$0.84.
Penumbra, Inc. has agreed to be acquired by Boston Scientific Corporation in a cash-and-stock merger. Under the Agreement and Plan of Merger, each issued and outstanding Penumbra share (other than excluded shares) will be converted into the right to receive either $374.00 in cash or 3.8721 Boston Scientific shares, subject to a proration mechanism that allocates 73.26% of outstanding Penumbra shares to cash consideration and 26.74% to stock consideration.
The Special Meeting of Penumbra stockholders is scheduled for May 6, 2026 to vote on adoption of the merger agreement. Boston Scientific is expected to issue approximately 43,866,267 shares in the transaction, with former Penumbra stockholders holding about 2.87% of Boston Scientific post-close, based on figures as of March 27, 2026.
Boston Scientific Corporation is registering shares in connection with its proposed acquisition of Penumbra, Inc. under an Amendment No. 1 to a Form S-4. Under the Agreement and Plan of Merger dated January 14, 2026, Penumbra will merge into a Boston Scientific subsidiary and Penumbra shareholders will receive, per Penumbra share, either $374.00 in cash or 3.8721 Boston Scientific Shares, subject to a proration mechanism that allocates 73.26% of Penumbra shares to cash and 26.74% to stock.
The proxy/prospectus sets the Special Meeting for May 6, 2026, describes election procedures and deadlines, treatment of equity awards (including a conversion formula and an Equity Award Stock Consideration of 1.0353 shares for certain awards), regulatory and closing conditions, appraisal rights, and termination fees of $525 million (to Boston Scientific in certain cases) and $900 million (to Penumbra in certain cases). Based on shares outstanding as of March 27, 2026, Boston Scientific expects to issue approximately 43,866,267 shares, with former Penumbra shareholders holding about 2.87% of Boston Scientific post-closing.
Boston Scientific filed an 8-K to share landmark clinical data for two cardiovascular therapies. The HI-PEITHO randomized trial in 544 patients with intermediate-risk pulmonary embolism showed the EKOS endovascular system plus anticoagulation was superior to anticoagulation alone on a composite endpoint (4.0% vs. 10.3%; 61% relative reduction), without intracranial bleeding through 30 days and with shorter hospital stays.
The CHAMPION-AF trial in 3,000 patients with non-valvular atrial fibrillation found the WATCHMAN FLX left atrial appendage closure device met all primary and secondary safety and efficacy endpoints versus leading blood thinners over 36 months, delivering markedly lower non-procedural bleeding (10.9% vs. 19.0%) and similar protection from stroke and cardiovascular death, with a 99% procedural success rate.
Boston Scientific Corp ownership disclosure: The Vanguard Group filed an amendment reporting that, after an internal realignment, it and certain subsidiaries will report beneficial ownership separately. The amendment states amount beneficially owned: 0 and percent of class: 0% as of the filing. The filing explains the disaggregation follows SEC Release No. 34-39538 and that subsidiaries pursue prior investment strategies.
Boston Scientific Corporation is asking stockholders to vote at a virtual 2026 Annual Meeting on April 30, 2026 at 8:00 a.m. Eastern Time. Holders of common stock at the close of business on March 6, 2026, when 1,486,175,167 shares were outstanding, may vote.
Stockholders are asked to elect ten directors, approve on an advisory basis the compensation of named executive officers, and ratify Ernst & Young LLP as independent auditor for the 2026 fiscal year. The Board recommends voting FOR all three items.
The agenda includes governance and capital proposals: amending the Employee Stock Purchase Plan to increase shares reserved; removing supermajority voting provisions; adding Delaware-permitted officer exculpation; and allowing stockholders holding 25% of common stock to call a special meeting. The Board supports these four proposals and recommends AGAINST a separate stockholder proposal titled “Give Shareholders the Ability to Call for a Special Shareholder Meeting.”